Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919253 | 0.92 | KMT2A (0.41) | KMT2ASMN1; SMN2KDM4EACHE | |
| SCHEMBL17946979 | 0.87 | KMT2A (0.47) | KMT2ASMN1; SMN2KDM4EACHEHRH3 | |
| SCHEMBL82103 | 0.81 | — | — | |
| SCHEMBL27258576 | 0.80 | KMT2A (0.45) | KMT2ASMN1; SMN2KDM4EACHE | |
| SCHEMBL11919058 | 0.79 | KMT2A (0.56) | KMT2ASMN1; SMN2KDM4EACHE | |
| SCHEMBL11919045 | 0.79 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHEHSD11B1 | |
| SCHEMBL4550252 | 0.78 | SMN1; SMN2 (0.44) | KMT2ASMN1; SMN2ACHEHSD11B1 | |
| SCHEMBL3439943 | 0.77 | KMT2A (0.50) | KMT2ASMN1; SMN2HRH3 | |
| SCHEMBL13548824 | 0.77 | KMT2A (0.50) | KMT2ASMN1; SMN2HSD11B1HRH3 | |
| SCHEMBL15806957 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KMT2A 2280/4885SMN1; SMN2 2262/4885KDM4E 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.